Search

The pathogenesis of chronic wounds (CW) involves a multifaceted interplay of biochemical, immunological, hematological, and microbiological interactions. Biofilm development is a significant virulence trait which enhances microbial survival and pathogenicity and has various implications on the development and management of CW. Biofilms induce a prolonged suboptimal inflammation in the wound microenvironment, associated with delayed healing. The composition of wound fluid (WF) adds more complexity to the subject, with proven pro-inflammatory properties and an intricate crosstalk among cytokines, chemokines, microRNAs, proteases, growth factors, and ECM components. One approach to achieve information on the mechanisms of disease progression and therapeutic response is the use of multiple high-throughput 'OMIC' modalities (genomic, proteomic, lipidomic, metabolomic assays), facilitating the discovery of potential biomarkers for wound healing, which may represent a breakthrough in this field and a major help in addressing delayed wound healing. In this review article, we aim to summarize the current progress achieved in host–microbiome crosstalk in the spectrum of CW healing and highlight future innovative strategies to boost the host immune response against infections, focusing on the interaction between pathogens and their hosts (for instance, by harnessing microorganisms like probiotics), which may serve as the prospective advancement of vaccines and treatments against infections. [ABSTRACT FROM AUTHOR]

Staphylococcus aureus, a prevalent human pathogen and a leading cause of hospital-acquired infections, is increasingly evolving antibiotic-resistant strains, increasing mortality and morbidity rates. Anti-staphylococcal vaccine research for prevention and treatment has become a priority. Antibodies against specific S. aureus components, toxins, and polysaccharides have demonstrated encouraging results in animal studies regarding protection against colonization or infection. However, human immunization trials have yielded less optimistic outcomes, with no anti-staphylococcal having passed clinical trials up to now. Although multiple formulation attempts triggered strong antibody responses, the vaccines could not effectively prevent S. aureus infections. This article delves into the results of immunotherapeutic strategies against S. aureus in both animal and human studies, discussing the feasibility of adequate immunization approaches against S. aureus in humans. [ABSTRACT FROM AUTHOR]

The genus Borrelia is represented by spirochetes that, once entered the human or animal body, can migrate to different organs, including the central nervous system. The aim of the study was to develop a murine neuroborreliosis model by inoculating a strain of Borrelia burgdorferi (Bb). 2 studies were conducted using BALB/c and CD1 mice strains, female, 8 weeks old, 22 grams at baseline. The selected animals were inoculated with Bb (106 spirochetes/mL), depending on the protocol, intradermally (100µL/animal) or intracerebrally (10µL/animal). For the evaluation of the neuroborreliosis development, endpoints were established at 1, 3, 6, 8 and 13 weeks post-infection, when samples of dura mater, brain, ear, heart, knee joint and bladder were collected, and maintained in culture medium specific for the growth of Borrelia. Recovery of Bb was possible from samples harvested 7 days post-infection from animals inoculated both intradermally and intracerebrally. Through the experiments we have developed a model of neuroborreliosis in two mice strains that can be useful for the study of the development of new therapeutic approaches. [ABSTRACT FROM AUTHOR]